Leukemia Clinical Trials in Massachusetts

Showing 1221-1240 of 1,253 trials

Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA)

NCT00878761

This Phase 2 study is a multi-center, randomized, double-blind, placebo-controlled, single followed by multiple dose, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and impact of STX-100 on gene and protein expression for αvβ6 related and TGF-β-inducible genes (including tubulointerstitial injury, epithelial function, and IF/TA related genes) in renal transplant patients with biopsy.

Chronic Allograft Dysfunction

Stromedix, Inc.48 participantsStarted Sep 2010

Cambridge, Massachusetts, United States

COMPLETEDPhase 226 miles

Study of Apremilast in Atopic or Contact Dermatitis

NCT00931242

The objective of this study is to evaluate the efficacy of apremilast in patients with recalcitrant atopic or contact dermatitis.

Atopic DermatitisAllergic Contact Dermatitis

Tufts Medical Center10 participantsStarted Jun 2009

Boston, Massachusetts, United States

UNKNOWNPhase 326 miles

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

NCT00715637

Amonafide is a DNA intercalating agent and inhibitor of topoisomerase II that has been extensively studied in patients with malignant solid tumors. Amonafide has also been studied in patients with AML. The purpose of this study is to assess the relative efficacy and safety of amonafide in combination with cytarabine compared to daunorubicin with cytarabine in subjects with documented secondary AML.

Secondary Acute Myeloid Leukemia (Secondary AML, sAML)

Antisoma Research420 participantsStarted Jun 2007

Los Angelas, California, United States • Los Angeles, California, United States • San Francisco, California, United States +155 more locations

Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA)

Study of Apremilast in Atopic or Contact Dermatitis

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Leukemia Trials in Other Cities

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer

Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)

Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)

A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube

A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season

Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases

CPG 7909 Injection in Non-Small Cell Lung Cancer

Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia

Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer

Study of Picoplatin Efficacy After Relapse

Other Conditions in Massachusetts